CSL Ltd Annual Report 2019

6 To meet growing global demand and to address unmet need for lifesaving medicines requires global capability. CSL has strategic manufacturing and distribution capability that positions us to meet the needs of patients and healthcare providers worldwide. Our strategy is to focus on efficiency across our business and to drive scale in our operations to supply the expanding global market. Global reach and focus CSL applies its world-class research and development (R&D), commercial strength and patient-focused management, along with its high-quality manufacturing, to develop and deliver innovative biotherapies, influenza vaccines and support programs. In the past five years, CSL has grown rapidly, due to strategic acquisitions, a rise in global demand for our products and investment in increased capacity. Our management team has significant experience in the industry and the confidence to drive our promise to patients into the next century. Our commitment to strategic sourcing rather than local sourcing has allowed the business to have a reliable supply of lifesaving therapies in multiple facilities across the globe. A number of CSL’s sites are supporting major capacity expansion projects from Project Sphinx in Marburg for HAEGARDA ® , Protinus in Bern for PRIVIGEN ® , Aurora in Broadmeadows for base fractionation and Atlas in Kankakee for base fractionation. In November 2018, we announced a US$140 million investment in a manufacturing expansion at Seqirus’ Holly Springs, US, facility, to meet the growing demand for vaccine products. These projects are timed to come on line ahead of demand to ensure a seamless supply of product to patients. Superior performance Our values We take pride in our results Beverly Fair, Manufacturing, Kankakee, US. CSL Limited Annual Report 2019 21 Global Reach and Impact